Claims for Patent: 6,329,181

Summary for Patent: 6,329,181

Title:	Helper functions for recombinant vector production
Abstract:	The present invention provides methods and compositions for preparations of recombinant parvovirus virions with a reduced number of replication competent particles. The compositions of the present invention include nucleic acids encoding parvovirus helper functions which contain at least one non-native intron sequence. The present invention also includes helper function vectors, host cells transfected with the helper function vectors, methods of using the helper function vectors, and recombinant parvovirus virions produced by such methods.
Inventor(s):	Xiao; Weidong (Jenkintown, PA), During; Matthew J. (Philadelphia, PA), Cao; Lei (Philadelphia, PA)
Assignee:	Neurologix, Inc. (Great Neck, NY)
Application Number:	09/633,566
Patent Claims:	1. A nucleic acid molecule encoding an adeno-associated virus (AAV) helper function, said nucleic acid molecule comprising: a Rep coding region derived from an AAV; a Cap coding region derived from an AAV; and at least one intron sequence inserted at one or more positions within the Cap coding region and the Rep coding region, such that the intron sequence increases the size of the nucleic acid molecule to a size larger than a nucleic acid molecule without the intron sequence, wherein the increase in size prevents packaging of a pseudo wild-type AAV into a replication competent particle. 2. The nucleic acid molecule of claim 1, wherein the AAV is selected from the group consisting of AAV-1, AAV-2, AAV-3, AAV4, AAV-5 and AAV-6. 3. The nucleic acid molecule of claim 1, wherein the intron sequence is an native intron sequence. 4. The nucleic acid molecule of claim 2, wherein the AAV is AAV-2. 5. The nucleic acid molecule of claim 4, wherein the intron sequence is an non-native intron sequence. 6. The nucleic acid molecule of claim 5, wherein the non-native intron sequence is selected from the group consisting of .alpha.-globulin intron, .beta.-globulin intron, collagen intron, ovalbumin intron, SV40 intron and p53 intron. 7. The nucleic acid molecule of claim 3, wherein the native intron sequence is an AAV intron sequence. 8. A nucleic acid molecule encoding an adeno-associated virus (AAV) helper function, said nucleic acid molecule comprising: a Cap coding region derived from an AAV; and at least one intron sequence inserted at one or more positions within the Cap coding region, such that the intron sequence increases the size of the nucleic acid molecule to a size larger than a nucleic acid molecule without the intron sequence wherein the increase in size prevents packaging of a pseudo wild-type AAV into a replication competent particle. 9. The nucleic acid molecule of claim 8, wherein the AAV is selected from the group consisting of AAV-1, AAV-2, AAV-3, AAV4, AAV-5 and AAV-6. 10. The nucleic acid molecule of claim 8, wherein the intron sequence is a non-native intron sequence. 11. The nucleic acid molecule of claim 8, wherein the intron sequence is a native intron sequence. 12. The nucleic acid molecule of claim 9, wherein the AAV is AAV-2. 13. The nucleic acid molecule of claim 10, wherein the non-native intron sequence is selected from the group consisting of .alpha.-globulin intron, .beta.-globulin intron, collagen intron, ovalbumin intron, SV40 intron and p53 intron. 14. The nucleic acid molecule of claim 11, wherein the native intron sequence is an AAV intron sequence. 15. A nucleic acid molecule encoding an adeno-associated virus (AAV) helper function, said nucleic acid molecule comprising: a Rep coding region derived from an AAV; and at least one intron sequence inserted at one or more positions within the Rep coding region, such that the intron sequence increases the size of the nucleic acid molecule to a size greater than a nucleic acid molecule without the intron sequence, wherein the increase in size prevents packaging of a pseudo wild-type AAV into a replication competent particle. 16. A helper function vector comprising the nucleic acid molecule of any one of claims 1, 8, or 15. 17. A host cell comprising the nucleic acid molecule of any one of claims 1, 8, or 15. 18. The nucleic acid molecule of claim 15, wherein the AAV is selected from the group consisting of AAV-1, AAV-2, AAV-3, AAV4, AAV-5 and AAV-6. 19. The nucleic acid molecule of claim 15, wherein the intron sequence is an non-native intron sequence. 20. The nucleic acid molecule of claim 15, wherein the intron sequence is an native intron sequence. 21. The nucleic acid molecule of claim 18, wherein the AAV is AAV-2. 22. The nucleic acid molecule of claim 19, wherein the non-native intron sequence is selected from the group consisting of .alpha.-globulin intron, .beta.-globulin intron, collagen intron, ovalbumin intron, SV40 intron and p53 intron. 23. The nucleic acid molecule of claim 20, wherein the native intron sequence is an AAV intron sequence. 24. The helper function vector of claim 16, wherein the vector is a plasmid. 25. The helper function vector of claim 16, wherein the vector is selected from the group consisting of adenovirus, herpesvirus and baculovirus. 26. A method of producing recombinant AAV virions comprising: introducing a AAV vector into a host cell; adding a helper function vector into the host cell, wherein the helper function vector comprises a nucleic acid molecule with a Cap coding region and a Rep coding region derived from an AAV, and at least one intron sequence inserted at one or more positions in the Cap coding region and the Rep coding region, such that the intron sequence increases the size of the nucleic acid molecule to a size larger than a nucleic acid molecule without the intron sequence, wherein the increase in size prevents packaging of a pseudo wild-type AAV into a replication competent particle; and culturing the host cell to produce recombinant AAV virions. 27. The method of claim 26, wherein the AAV vector is selected from the group consisting of AAV-1, AAV-2, AAV-3, AAV-4, AAV-5 and AAV-6. 28. The method of claim 26, wherein the helper function vector comprises a nucleic acid molecule with a Cap coding region and a Rep coding region derived from an AAV selected from the group consisting of AAV-1, AAV-2, AAV-3, AAV-4, AAV-5 and AAV-6. 29. The method of claim 26, wherein the intron sequence is a non-native intron sequence. 30. The method of claim 26, wherein the non-native intron sequence is selected from the group consisting of .alpha.-globulin intron, .beta.-globulin intron, collagen intron, ovalbumin intron, SV40 intron and p53 intron. 31. The method of claim 26, wherein the intron-sequence is a native intron sequence. 32. The method of claim 26, wherein the helper function vector is selected from the group consisting of a plasmid, phage, transposon, cosmid, and virus. 33. The method of claim 31, wherein the native intron-sequence is an AAV intron sequence. 34. A method of producing recombinant AAV virious comprising: introducing an AAV vector into a host cell; adding a first helper function vector into the host cell, wherein the first helper function vector comprises a nucleic acid molecule encoding an AAV region selected from the group consisting of a Cap coding region and a Rep coding region, and at least one intron sequence inserted in at least one position within said regions, such that the intron sequence increases the size of the nucleic acid molecule to a size larger than a nucleic acid molecule without the intron sequence, wherein the increase in size prevents packaging of a pseudo wild-type AAV into a replication competent particle; and culturing the host-cell to produce recombinant AAV virions. 35. The method of claim 34, further comprising introducing a second helper function vector into a host cell, wherein the second helper function vector comprises a nucleic acid molecule encoding an AAV region selected from the group consisting of a Cap coding region and a Rep coding region, wherein the second helper function vector is different from the first helper function vector. 36. The method of claim 34, further comprising introducing a second helper function vector into a host cell, wherein the second helper function vector comprises a nucleic acid molecule encoding an AAV region selected from the group consisting of a Cap coding region and a Rep coding region, and an intron sequence inserted in at least one position in said regions, wherein the second helper function vector is different from the first helper function vector. 37. The method of claim 34, wherein the AAV vector is selected from the group consisting of AAV-1, AAV-2, AAV-3, AAV4, AAV-5 and AAV6. 38. The method of claim 34, wherein the first helper function vector comprises a nucleic acid molecule encoding an AAV region derived from an AAV selected from the group consisting of AAV-1, AAV-2, AAV-3, AAV4, AAV-5 and AAV-6. 39. The method of claim 34, wherein the first helper function vector is selected from the group consisting of a phage, transposon, cosmid, and virus. 40. The method of claims 34, 35 and 36, wherein the intron sequence is a non-native intron sequence. 41. The method of claims 34, 35, and 36, wherein the intron sequence is a native intron sequence. 42. The method of claims 35 and 36, wherein the second helper function vector comprises a nucleic acid molecule encoding an AAV region derived from an AAV selected from the group consisting of AAV-1, AAV-2, AAV-3, AAV-4, AAV-5 and AAV-6. 43. The method of claims 35 and 36, wherein the second helper function vector is selected from the group consisting of a phage, transposon, cosmid, and virus. 44. The method of claim 40, wherein the non-native intron sequence is selected from the group consisting of .alpha.-globulin intron, .beta.-globulin intron, collagen intron, ovalbumin intron, SV40 intron and p53 intron. 45. The method of claim 41, wherein the native intron sequence is an AAV intron sequence.

Details for Patent 6,329,181

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26